Revusiran

Drug Profile

Revusiran

Alternative Names: ALN-TTRsc; SAR438714; siTTRsc

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class Heart failure therapies; Small interfering RNA
  • Mechanism of Action Prealbumin inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Amyloid polyneuropathy; Cardiomyopathies

Most Recent Events

  • 08 Feb 2017 Alnylam Pharmaceuticals terminates a phase III extension trial for familial amyloidotic Cardiomyopathy (In the elderly, In adults) due to safety findings in United Kingdom (SC) (EudraCT2015-005333-49)
  • 01 Feb 2017 Alnylam Pharmaceuticals completes a phase II trial in Amyloid polyneuropathy in France, Germany, Portugal, Sweden, United Kingdom (SC) (NCT02595983)
  • 01 Nov 2016 Alnylamt terminates a phase III trial in Cardiomyopathy (In adults, In the elderly) due to unacceptable risk benefit profile in USA, United Kingdom, Belgium, Canada, France, Germany, Italy, Sweden and Spain (SC) (NCT02319005)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top